source
- CG Oncology's bladder cancer immunotherapy cuts tumor recurrence risk by 68% in studyCG Oncology reported that its bladder cancer immunotherapy, cretostimogene, achieved a 68% reduction in tumor recurrence compared with standard care. The treatment uses an engineered common cold v…
- Biotech sector rebounds but gains are uneven, with Chinese firms and a large Sofinnova fund leading the surgeBiotech companies are experiencing a strong year overall, yet investor reactions to positive clinical data remain mixed. Chinese biotech firms are emerging as the top performers, outpacing many pe…